OncoMatch/Clinical Trials/NCT06727630

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

Is NCT06727630 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies PRJ1-3024 for melanoma.

Phase 1/2RecruitingZhuhai Yufan Biotechnologies Co., LtdNCT06727630Data as of May 2026

Treatment: PRJ1-3024 — This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma

Check if I qualify

Extracted eligibility criteria

Cancer type

Melanoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: systemic standard therapy

Patients who have progressed or relapsed after at least 1st-line systemic standard therapy

Cannot have received: hematopoietic progenitor kinase 1 (HPK1) inhibitor

Prior treatment with other hematopoietic progenitor kinase 1 (HPK1) inhibitors

Lab requirements

Blood counts

adequate hematologic parameters

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify